Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108:353–66.
Google Scholar
Hackl H, Astanina K, Wieser R. Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. J Hematol Oncol. 2017;10:51.
Google Scholar
Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia. 2011;25:1239–48.
Google Scholar
Bernt KM, Armstrong SA. Targeting epigenetic programs in MLL-rearranged leukemias. Hematol Am Soc Hematol Educ Program. 2011;2011:354–60.
Google Scholar
Shahswar R, Gabdoulline R, Krueger K, Wichmann M, Gotze KS, Braitsch K, et al. A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. Leukemia. 2025;39:614–22.
Google Scholar
Bataller A, Goulart HE, Issa GC, DiNardo CD, Daver N, Kadia T, et al. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia. 2025;39:1640–9.
Gil KB, Borg J, Pereira RM, Inguva-Sheth A, Araujo G, Rahkola J, et al. The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells. Haematologica. 2026;111:481–92.
Nishida Y, Ishizawa J, Ayoub E, Montoya RH, Ostermann LB, Muftuoglu M, et al. Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias. Sci Adv. 2023;9:eadh1436.
Google Scholar
Zhao Q, Liu H, Peng J, Niu H, Liu J, Xue H, et al. HDAC8 as a target in drug discovery: function, structure and design. Eur J Med Chem. 2024;280:116972.
Google Scholar
An P, Chen F, Li Z, Ling Y, Peng Y, Zhang H, et al. HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3beta/Snail signals. Oncogene. 2020;39:4956–69.
Google Scholar
Emmons MF, Bennett RL, Riva A, Gupta K, Carvalho L, Zhang C, et al. HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis. Nat Commun. 2023;14:7759.
Google Scholar
Chang TY, Yan Y, Yu ZY, Rathore M, Lee NZ, Tseng HJ, et al. Combined HDAC8 and checkpoint kinase inhibition induces tumor-selective synthetic lethality in preclinical models. J Clin Investig. 2024;134:e165448.
Amin SA, Khatun S, Gayen S, Das S, Jha T. Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)? Eur J Med Chem. 2023;258:115594.
Google Scholar
Qi J, Singh S, Hua WK, Cai Q, Chao SW, Li L, et al. HDAC8 inhibition specifically targets Inv(16) acute myeloid leukemic stem cells by restoring p53 acetylation. Cell Stem Cell. 2015;17:597–610.
Google Scholar
Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, et al. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia. Blood. 2020;135:1472–83.
Google Scholar
Spreafico M, Gruszka AM, Valli D, Mazzola M, Deflorian G, Quinte A, et al. HDAC8: a promising therapeutic target for acute myeloid leukemia. Front Cell Dev Biol. 2020;8:844.
Google Scholar
Hua WK, Qi J, Cai Q, Carnahan E, Ayala Ramírez M, Li L, et al. HDAC8 regulates long-term hematopoietic stem-cell maintenance under stress by modulating p53 activity. Blood. 2017;130:2619–30.
Google Scholar
Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739–43.
Google Scholar
Brunner AM, Graubert TA. Genomics in childhood acute myeloid leukemia comes of age. Nat Med. 2018;24:7–9.
Google Scholar
Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103–12.
Google Scholar
Higuchi T, Nakayama T, Arao T, Nishio K, Yoshie O. SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma. Blood. 2013;121:3640–9.
Google Scholar
Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2024;52:D174–82.
Google Scholar
Huang WJ, Wang YC, Chao SW, Yang CY, Chen LC, Lin MH, et al. Synthesis and biological evaluation of ortho-aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors. ChemMedChem. 2012;7:1815–24.
Google Scholar
Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022;6:2847–53.
Google Scholar
Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008;22:1026–34.
Google Scholar
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003l;34:267–73.
Google Scholar
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.
Google Scholar
Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, et al. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022;139:584–96.
Google Scholar
Zhang L, Nguyen LXT, Chen YC, Wu D, Cook GJ, Hoang DH, et al. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. Nat Commun. 2021;12:6154.
Google Scholar
Xu G, Wang F, Chen M, Gao W, Liu Y, Zhu J, et al. Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1alpha. Leukemia. 2025;39:2640–51.
Wiederschain D, Kawai H, Gu J, Shilatifard A, Yuan ZM. Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL. Mol Cell Biol. 2003;23:4230–46.
Google Scholar
Wiederschain D, Kawai H, Shilatifard A, Yuan ZM. Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. J Biol Chem. 2005;280:24315–21.
Google Scholar
Wang B, Xu L, Zhang J, Cheng X, Xu Q, Wang J, et al. LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p. Biomed Pharmacother. 2020;129:110268.
Google Scholar
Tang X, Li G, Su F, Cai Y, Shi L, Meng Y, et al. HDAC8 cooperates with the SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration. Nucleic Acids Res. 2020;48:2912–23.
Google Scholar
Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6:a026831.
Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6:238–43.
Google Scholar
Sarkar K, Debnath S, Sen D, Kar S, Sil SK. Crucial structural understanding for selective HDAC8 inhibition: common pharmacophores, molecular docking, molecular dynamics, and zinc binder analysis of selective HDAC8 inhibitors. Med Chem. 2024.
Rajaraman S, Balakrishnan R, Deshmukh D, Ganorkar A, Biswas S, Pulya S, et al. HDAC8 as an emerging target in drug discovery with special emphasis on medicinal chemistry. Future Med Chem. 2023;15:885–908.
Google Scholar
Hossain DM, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, et al. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood. 2014;123:15–25.
Google Scholar
Zhang Q, Hossain DM, Duttagupta P, Moreira D, Zhao X, Won H, et al. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. Blood. 2016;127:1687–1700.
Google Scholar
Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11:1314–21.
Google Scholar
Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol. 2008;20:228–33.
Google Scholar
Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7:41–51.
Google Scholar
Fornek JL, Tygrett LT, Waldschmidt TJ, Poli V, Rickert RC, Kansas GS. Critical role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood. 2006;107:1085–91.
Google Scholar
Avery DT, Ma CS, Bryant VL, Santner-Nanan B, Nanan R, Wong M, et al. STAT3 is required for IL-21-induced secretion of IgE from human naive B cells. Blood. 2008;112:1784–93.
Google Scholar
Nwosu GO, Ross DM, Powell JA, Pitson SM. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis. 2024;15:413.
Google Scholar
Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D’Alessandro A, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019;9:910–25.
Google Scholar
Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022;5:380–400.
Google Scholar
Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, et al. Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy. Cancer Cell. 2017;32:748–60.e746.
Google Scholar
Chakraborty S, Morganti C, Pena BR, Zhang H, Verma D, Zaldana K, et al. A STAT3 degrader demonstrates pre-clinical efficacy in Venetoclax-resistant acute myeloid leukemia. Leukemia. 2026;40:717–29.
Lu Y, Jiang X, Li Y, Li F, Zhao M, Lin Y, et al. NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia. J Transl Med. 2024;22:867.
Google Scholar
Zhang P, Brinton LT, Williams K, Sher S, Orwick S, Tzung-Huei L, et al. Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition. Clin Cancer Res. 2021;27:2352–66.
Google Scholar
Bass AKA, El-Zoghbi MS, Nageeb EM, Mohamed MFA, Badr M, Abuo-Rahma GEA. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. Eur J Med Chem. 2021;209:112904.
Google Scholar
Hou S, Liu J, Zhu Y. Multi-omics advances for molecular characterization, precision medicine, and prognostic implications in leukemia. Cell Investig. 2025;1:100007.
Google Scholar
Ghazy E, Zeyen P, Herp D, Hugle M, Schmidtkunz K, Erdmann F, et al. Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1. Eur J Med Chem. 2020;200:112338.
Google Scholar
Jia C, Liang Z, Yao X, Lin Q, Zhang Y. CRISPR libraries: a powerful screening tool for function and mechanism study of cancer. Cell Investig. 2025;1:100044.
Google Scholar
